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Objective: The purpose of this study was to improve skin permeation of evodiamine and 
rutaecarpine for transdermal delivery with microemulsion as vehicle and investigate real-time 
cutaneous absorption of the drugs via in vivo microdialysis.
Methods: Pseudoternary phase diagrams were constructed to evaluate microemulsion regions 
with various surfactants and cosurfactants. Nine formulations of oil in water microemulsions 
were selected as vehicles for assessing skin permeation of evodiamine and rutaecarpine in 
ex vivo transdermal experiments. With a microdialysis hollow fiber membrane implanted in 
the skin beneath the site of topical drug administration, dialysis sampling was maintained for 
10 hours and the samples were detected directly by high performance liquid chromatography. 
Real-time concentrations of the drugs in rat skin were investigated and compared with those of 
conventional formulations, such as ointment and tincture. Furthermore, the drugs were applied 
to various regions of the skin using microemulsion as vehicle.
Results: In ex vivo transdermal experiments, cutaneous fluxes of evodiamine and rutaecarpine 
microemulsions were 2.55-fold to 11.36-fold and 1.17-fold to 6.33-fold higher, respectively, 
than those of aqueous suspensions. Different drug loadings, microemulsion water content, and 
transdermal enhancers markedly influenced the permeation of evodiamine and rutaecarpine. 
In microemulsion application with in vivo microdialysis, the maximum concentration of the 
drugs (evodiamine: 18.23 ± 1.54 ng/mL; rutaecarpine: 16.04 ± 0.69 ng/mL) were the highest, 
and the area under the curve0–t of evodiamine and rutaecarpine was 1.52-fold and 2.27-fold 
higher than ointment and 3.06-fold and 4.23-fold higher than tincture, respectively. A greater 
amount of drugs penetrated through and was absorbed by rat abdominal skin than shoulder 
and chest, and a reservoir in the skin was found to supply drugs even after the microemulsion 
was withdrawn.
Conclusion: Compared to conventional formulations, higher cutaneous fluxes of evodiamine 
and rutaecarpine were achieved with microemulsion. Based on this novel transdermal delivery, 
the transdermal route was effective for the administration of the two active alkaloids.
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Introduction
Evodiae fructus is the dried and unripe fruit of Evodia rutaecarpa (Juss) Benth. 
E. rutaecarpa (Juss) Benth. var. officinalis (Dode) Huang or E. rutaecarpa (Juss) 
Benth. var. bodinieri (Dode) Huang is also known as Wuzhuyu in China and has a 
long history of common use as a traditional Chinese medicine. Wuzhuyu was officially 
listed in the Pharmacopoeia of the People’s Republic of China for oral administration 
or navel application of the powder mixed with vinegar for the treatment of headache, 
abdominal pain, difficult menstruation, vomiting, diarrhea, and other diseases.1 
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Evodiamine (Evo) and rutaecarpine (Rut) are the main active 
ingredients isolated from E. fructus.2 With respect to the 
pharmacological actions of Evo and Rut, more attention has 
been paid to their antinociceptive activity and antiinflam-
matory effects.3–6 In the authors’ previous studies, topical 
administration of Evo and Rut at a ratio of 1:1 (w/w) elicited 
good antiinflammatory and analgesic effects in mice. Thus, 
Evo and Rut have the potential to be developed into topical 
antiphlogistic and analgesic preparations.
Evo and Rut are both sparingly soluble, small molecules 
(Figure 1) that must be carried by an appropriate agent at a 
therapeutic dose for transdermal delivery in the clinic. A rate-
limiting step in transdermal drug delivery is the permeation 
through the stratum corneum. Thus, methods to improve skin 
penetration of active ingredients to achieve therapeutically 
relevant levels are critical for transdermal formulations. 
However, the high solubilities and permeation fluxes required 
by regular formulations, such as tinctures and ordinary 
creams, are difficult to achieve with Evo and Rut.
A microemulsion (ME) is a dispersion with a droplet 
diameter usually within the range of 10–100 nm.7 During 
recent decades, numerous studies have suggested that MEs 
have the potential to increase cutaneous drug delivery of both 
hydrophilic and lipophilic drugs compared to conventional 
vehicles.8 MEs are associated with enhanced drug solubility, 
thermodynamic activity towards skin, enhancement of ME 
component permeation, ease of formulation, and thermody-
namic stability of the system.9,10 In this paper, because of the 
sparing solubilities of both Evo and Rut in aqueous solution, 
oil in water (O/W) MEs were employed as transdermal 
vehicles for improving the solubility and subsequent skin 
flux of each drug. The formulations of Evo and Rut-loaded 
MEs were optimized mainly through ex vivo skin permeation 
experiments. The characteristics of the prepared MEs and 
the stability of drug-loaded MEs prepared according to an 
optimal formulation were evaluated.
To further investigate skin permeation characteristics of 
the MEs, microdialysis was used to assess drug   concentrations 
in the skin.11 Microdialysis is a minimally invasive, in 
vivo sampling technique for measuring concentrations of 
endogenous and exogenous substances in the extracellular 
space of tissues or organs in the body. Dialysis is the process 
of sampling fluid in the in vivo environment using a semiper-
meable membrane that allows biological molecules to diffuse 
into a sample via a concentration gradient.12 Preliminary 
results have demonstrated the ability of microdialysis probes 
to continuously monitor the concentrations of drugs in the 
dermis in vivo. Besides assessing actual skin concentrations 
in vivo, the microdialysis technique was successfully used 
for obtaining a reliable pharmacokinetic model to estimate 
cutaneous permeation on a routine basis.13 The aim of this 
study was to evaluate transdermal drug delivery of Evo and 
Rut in rats using the in vivo microdialysis technique. To 
this end, different dosages and formulations of Evo and Rut 
(ie, tincture, ointment, and ME) were used on different regions 
of rat skin (eg, abdomen or shoulder). The dialysate samples 
were analyzed by high performance liquid chromatography 
(HPLC), and in vivo recovery of the probe was assessed 
with the retrodialysis method. Performance of the ME was 
compared with the performance of conventional forms to 
evaluate its potential for enhancing transdermal delivery.
The focus of this study was the application of in vivo 
microdialysis to assess transdermal drug delivery, and the 
innovation was to investigate the percutaneous absorption 
of drugs by different regions of the skin (eg, abdomen or 
shoulder) via microdialysis.
Materials and methods
Materials
Evo and Rut (purity . 98%, determined by HPLC) were both 
provided by Linuo Biotechnology Co, Ltd (Zhengzhou, China). 
Ethyl oleate was purchased from Shanghai Yunhong Chemical 
Preparation Auxiliary Technology Co, Ltd (Shanghai, China). 
Polyethylene glycol (PEG)-35 castor oil (Cremophor® EL) was 
obtained from BASF (Ludwigshafen, Germany) and all other 
chemicals were from Sinopharm Chemical Reagent Co, Ltd 
(Shanghai, China), and were of HPLC or analytical grade.
Animals
Male Sprague-Dawley rats of clean grade, weighing 
  180–220 g, were used. The animal study was conducted 
in accordance with the approval of the Animal Ethical 
  Committee, Shanghai University of Traditional Chinese 
Medicine. Animals were kept in an agreeable environment 
with free access to rodent diet and water, and were acclima-
tized for at least 1 week before start of the study.
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Figure 1 Structures of evodiamine (A) and rutaecarpine (B).
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HPLC analysis of Evo and Rut
The  LC-2010A  HT  Liquid  Chromatograph  system 
  (Shimadzu Corporation, Kyoto, Japan) was used for dialysate 
sample analysis to detect the presence of Evo and Rut and to 
determine their concentrations. The HPLC system consisted 
of a double plunger pump (Shimadzu Corporation, Kyoto, 
Japan), an autosampler (Shimadzu Corporation), an online 
degasser (Shimadzu Corporation), a Diamonsil C18 reverse 
phase column (5 µm, 4.6 mm inner diameter × 25 cm; Dikma 
Technologies, Inc, Beijing, China), a column oven (Shimadzu 
Corporation), an ultraviolet detector (Hamamatsu Photonics, 
Hamamatsu, Japan), and a recording   integrator (Shimadzu 
Corporation). The mobile phase was acetonitrile:water (43:57, 
v/v) containing 0.04% (w/v) sodium 1-  octanesulfonate with 
a flow of 1 mL/min. The column temperature was constant at 
35°C and the detection wavelength was 225 nm.   Percentage 
recoveries ranged from 98.6%–101.2%. The intra-day   relative 
standard deviation values were 0.25% for Evo and 0.31% 
for Rut, and inter-day relative standard deviation values 
were 1.58% and 1.74% for Evo and Rut,   respectively. The 
samples from ex vivo experiments were filtered through a 
nylon 0.45 µm pore size disposable syringe filter   (diameter: 
13 mm [Shanghai Anpel Scientific Instrument Inc, Shanghai, 
China]) before automatic injection with HPLC, and the 
samples from in vivo microdialysis were directly assayed in 
a timely manner without any handling.
Construction of pseudoternary phase  
diagrams
Pseudoternary phase diagrams were constructed using the 
water titration method at 25°C to investigate the concentration 
range of components for ME formation. For the preparation 
of each phase diagram, the weight ratios of oil in a mixture 
of surfactant and cosurfactant were set at 1:9, 2:8, 3:7, 4:6, 
5:5, 6:4, 7:3, 8:2, and 9:1. To each mixture of oil, surfactant, 
and cosurfactant as above, water was added dropwise under 
magnetic stirring at 300 rpm. After   equilibration, the mixtures 
were visually assessed and determined as being MEs, crude 
emulsions, or gels.
Preparation of Evo and Rut MEs
Based on the phase diagrams, the compositions of ME1 to 
ME9 were determined for various surfactants and cosurfac-
tants, as listed in Table 1. For the preparation of each ME, 
Evo and Rut were accurately weighed and added to a mixture 
of ethyl oleate, surfactant, and cosurfactant, and stirred for 
about 1 hour with a polytetrafluoroethylene magnetic stir 
bar (length: 3 cm [Shanghai Xinpei Technology Inc, Shang-
hai, China]) at 300 rpm to dissolve the drugs. The required 
amount of water was then added dropwise under magnetic 
stirring at 300 rpm to form the ME. The loading of each drug 
was 2.0% (w/w) in all the prepared MEs; the water content 
of all nine formulations was 50% (w/w). To further optimize 
the formulation, ME2 was prepared with different drug 
loadings and water content and with or without permeation 
enhancers. To evaluate the permeation enhancers, defined 
levels of volatile oils or azone were directly added to the 
prepared MEs, and magnetically stirred for 0.5 hours at 
300 rpm. Every sample of the prepared ME weighed 200 g. 
All the operations were performed at room temperature.
ME characterization
The viscosities of the prepared MEs were measured using 
a DV-I + Digital Viscometer (Brookfield Engineering 
  Laboratories Inc, Middleboro, MA) with No. 1 rotor set at 
100 rpm, and the pH values were determined with a Jenway 
  Digital pH Meter (Bibby Scientific Limited, Staffordshire, 
United Kingdom) at 25°C. The average droplet sizes of the pre-
pared MEs were measured by photocorrelation spectroscopy 
using Nicomp 380/ZLS Instrument (PSS, Port Richey, FL).   
Table 1 Compositions and drug loadings of microemulsions ME1–ME9
Formulations Weight fractions of components (%) Drug loading (%)
Surfactant Cosurfactant Ethyl oleate Water Evodiamine Rutaecarpine
ME1 Cremophor® EL 33.8 PEg400 11.2 5.0 50.0 2.0 2.0
ME2 Cremophor® EL 30.0 PEg400 15.0 5.0 50.0 2.0 2.0
ME3 Cremophor® EL 22.5 PEg400 22.5 5.0 50.0 2.0 2.0
ME4 Cremophor® EL 33.8 Ethanol 11.2 5.0 50.0 2.0 2.0
ME5 Cremophor® EL 30.0 Ethanol 15.0 5.0 50.0 2.0 2.0
ME6 Cremophor® EL 22.5 Ethanol 22.5 5.0 50.0 2.0 2.0
ME7 Tween®-80 33.8 Ethanol 11.2 5.0 50.0 2.0 2.0
ME8 Tween®-80 30.0 Ethanol 15.0 5.0 50.0 2.0 2.0
ME9 Tween®-80 22.5 Ethanol 22.5 5.0 50.0 2.0 2.0
Abbreviation: PEg, polyethylene glycol.
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The appearance of the MEs was examined using a transmission 
electron microscope (Philips Tecnai 12; Philips, Amsterdam, 
the Netherlands). The samples were prepared for negative 
staining as follows: copper nets carrying formvar-supporting 
film (Zhong Jing Ke Yi Technology Inc, Beijing, China) were 
placed onto a stencil plate. MEs were dropped gently onto the 
film, and the film was allowed to dry for about 20 minutes. 
A drop of 2% phosphotungstic acid was then added to the 
film and allowed to dry for 10 minutes, and the film was then 
observed under a transmission electron microscope.
Preparation of formulations  
for comparison
The ointments used for comparison included 13% stearic 
acid, 6.5% glyceryl monostearate, 0.3% sodium lauryl sulfate, 
2% liquid paraffin, 13% glycerol, 6.5% Vaseline® (Unilever, 
London, UK), 0.3% triethanolamine, and water. Stearic acid, 
glyceryl monostearate, liquid paraffin, and Vaseline were used 
as the oil phase and were mixed together in a water bath at 70°C 
until a clear liquid was obtained. The drugs were then added 
and dissolved; other components were in the aqueous phase 
and were mixed at 70°C. Then, the oil phase was mixed into 
the aqueous phase under stirring and was stirred continuously 
until the mixture cooled to room temperature and turned into a 
uniform white ointment. The aqueous suspension was prepared 
with pure water, and the tincture with 70% (w/w) ethanol. The 
concentrations of Evo and Rut in the compared ointment, aque-
ous suspension, and tincture were identical to those in the ME. 
For microdialysis study, the penetration enhancer azone (1% 
w/w) was added to the MEs, ointment, and tincture.
Ex vivo skin permeation studies
The ex vivo penetration experiments were carried out with a 
Franz diffusion cell (Tianjin Fulansi Electronic Science and 
Trade Co, Ltd, Tianjin, China) fitted with excised rat skin, 
and the prepared MEs were compared with Evo and Rut 
aqueous suspension and ointment.14 To each donor compart-
ment with a diffusion area of 1.77 cm2, 2 g of ME, aqueous 
suspension, or ointment was added and sealed with parafilm. 
Each receptor compartment, with a volume of 16 mL, was 
filled with freshly prepared 30% ethanol in water (3:7 v/v) to 
provide sink conditions, thermostated at 32°C, ± 0.5°C, and 
stirred with a magnetic bar at 300 rpm. Each experiment was 
performed in triplicate. At predetermined time points, 1 mL 
samples were removed from each receptor compartment, 
which was replenished with an equal volume of receptor 
fluid equilibrated to 32°C, ± 0.5°C. The concentrations of 
Evo and Rut in the obtained samples were determined by 
HPLC.15 Permeation profiles for Evo and Rut were obtained 
by plotting the mean cumulative permeation amounts per 
cm2 of MEs, aqueous suspension, or ointment against time. 
Linear regression analysis was performed to determine skin 
fluxes (Js, µg/cm2/hour) of Evo and Rut.
Stability of MEs
For stability evaluation, Evo and Rut-loaded MEs prepared 
according to optimal formulation were stored at 25°C for 
6 months. The physical stability of each ME was evaluated 
monthly through observation of physical changes, such as 
phase separation, flocculation and/or precipitation, droplet 
size change, and a centrifugation stability test at 10,000 rpm 
for 30 minutes. Chemical stability was evaluated monthly by 
measuring Evo and Rut concentrations using HPLC.
Microdialysis system
The microdialysis system consisted of a WZ-50C6 Micro 
Infusion pump (Smiths Medical, Norwell, MA) with a 20 mL 
plastic syringe and a linear microdialysis probe. The Spectra/
Por® Microdialysis Hollow Fibers (Spectrum Laboratories, 
Inc, Chicago, IL) were prepared using regenerated cellulose 
(200 µm inner diameter, 280 µm outer diameter, 13,000 Da 
molecular weight cut-off). The fiber was glued with cyano-
acrylate adhesive (MXBON® Super Glue; Cartell Chemical Co 
Ltd, Chia-Yi Hsien, Taiwan) to quartz capillary tubing (Welch 
Materials, Inc, Shanghai, China) to make linear microdialysis 
probes. The inlet tube of the probe was connected to the micro-
injection pump using polyethylene tubing. In all experiments, 
the length of the membrane accessible to dialysis was approxi-
mately 20 mm, and the perfusate flow rate was 0.2 mL/hour 
(3.33 µL/minute). Cannulas were used as insertion guides, and 
vials were used to collect the dialysate samples.
Standard (STD) solutions of Evo and Rut were prepared 
by dissolving pure Evo and Rut in 10% (w/w) ethanol 
solution. The concentrations of the STD solutions were as 
follows: STD1 (0.40 µg/mL), STD2 (0.80 µg/mL), STD3 
(1.60 µg/mL), STD4 (2.40 µg/mL), STD5 (3.20 µg/mL), and 
STD6 (4.00 µg/mL). An aqueous solution of urethane 20% 
(w/w) was used in the experiments.
Ex vivo recovery validation
Ex vivo recovery was estimated prior to the onset of microdi-
alysis studies to ensure that the probes used would provide 
reproducible and efficient sampling.
A linear probe was placed in a 50 mL beaker contain-
ing STD3 solution, and the dialysis membrane part of the 
probe was completely immersed in the solution at room 
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  temperature. The probe was perfused with 10% (w/w) ethanol 
solution under a flow rate of 0.2 mL/hour (3.33 µL/minute). 
After an equilibration period of 30 minutes, the dialysate was 
collected into a small vial for 30 minutes. Then, the dialysate 
sample was analyzed by HPLC for determining the concentra-
tions of Evo and Rut. Relative recovery (RR) was calculated 
as the slope of the linear regression of drug concentration in 
the dialysate (Cd) as a function of drug concentration in the 
medium (Cm) (Equation 1).
  RR
C
C
d
m
=   (1)
For the retrodialysis studies, the probe was perfused 
with STD solutions containing different concentrations of 
Evo and Rut (STD1, STD2, STD3, STD4, STD5, and STD6) 
in sequence. A linear probe was placed in a 50 mL beaker 
with the membrane part completely immersed in 10% (w/w) 
ethanol solution at room temperature. STD1 was first used as a 
perfusate at a flow rate of 3.33 µL/minute. After equilibration 
for 30 minutes, the dialysate sample was collected into a vial 
for another 30 minutes. Next, STD1 was replaced with STD2, 
STD3, STD4, STD5, and STD6 in order, and the procedure was 
repeated as above with the ethanol solution refreshed each 
time. The diffusive loss of Evo and Rut from perfusates was 
determined, and RR was calculated using Equation 2, where 
Cp is the drug concentration in the perfusate.
  RR
CC
C
pd
p
=
−
  (2)
The retrodialysis method was also used to study the 
influence of various flow rates on recovery of the probe. 
Again, a linear probe was placed in a 50 mL beaker with 
the membrane part completely immersed in 10% (w/w) 
ethanol solution at room temperature. STD3 solution was 
selected as the perfusate, and the probe was perfused at 
flow rates of 0.1 mL/hour (1.67 µL/minute), 0.2 mL/hour 
(3.33 µL/minute), 0.3 mL/hour (5 µL/minute), 0.4 mL/hour 
(6.67 µL/minute), and 0.5 mL/hour (8.33 µL/minute). For 
each flow rate, the dialysate sample was collected after 
30 minutes equilibration. Five dialysate samples were 
obtained for each probe and further analyzed by HPLC. Using 
Equation 2, RR was calculated for each flow rate.
In vivo microdialysis studies
Probe implantation
A male Sprague-Dawley rat, weighing about 200 g, was 
anesthetized with urethane aqueous solution (1.3 g/kg, 
intraperitoneally), and anesthesia was maintained throughout 
the experiment. Abdominal fur was manually clipped with a 
blade, taking care not to damage the skin. The rat was immobi-
lized on a mat with the abdomen facing upward. The ambient 
temperature was kept constant at 25°C. Probe insertion was 
accomplished with a hypodermic needle, which served as a 
guide cannula. An entry puncture was made in the skin, and 
the needle was inserted through the skin for an appropriate 
length (20–25 mm) before leaving the skin via an exit   puncture. 
The microdialysis probe was then inserted through the guide 
  cannula, which was then retracted to expose the active dialysis 
window beneath the site of topical drug administration. The 
insertion guide was removed and the inlet tube was attached 
to the microinjection pump via connecting tubing. After probe 
implantation, the skin was visually inspected for punctures. 
The probe was also implanted under the skin of the shoulder 
or chest in the same manner as above.
In vivo microdialysis sampling
Following probe implantation, the connective tubing from 
the probe was immobilized with adhesive tape to secure its 
position in the skin. After making sure that the tubing was 
unblocked, perfusion was initiated with the microdialysis 
pump at a flow rate of 0.2 mL/hour (3.33 µL/minute). The 
probe was continuously perfused with 10% (w/w) ethanol 
solution. The skin was allowed to equilibrate for 1 hour before 
a blank sample was taken. At 1.5 hours after perfusion, the 
drug was applied. Due to fluidity, cotton wool soaked with 
the ME (2 g) or tincture (2 g) was applied on the skin above 
the probe. The ointment (2 g) was applied directly on the skin 
above the probe. Dialysate samples were collected into small 
vials, and the collection vial was replaced every 30 minutes. 
Dialysis sampling was maintained for 10 hours. The ME, 
tincture, and ointment were all tested on the abdominal 
region, while ME was also tested on the shoulder and chest 
regions. Furthermore, another experiment was carried out in 
which the ME was removed after a 3 hour application on the 
abdominal skin.
In vivo recovery correction
In vivo RR was estimated in separate experiments subsequent 
to microdialysis studies, using the retrodialysis-by-drug 
method, which relies on the assumption that net drug transport 
from the perfusate into the surrounding tissues through the 
microdialysis membrane equals the net drug transport from 
the tissues into the perfusate.16 The diffusive loss of the drugs 
of interest was determined, and RR was calculated using 
Equation 2.
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In this experiment, a linear probe was inserted into the 
dermis of an anesthetized rat’s abdominal skin, as described 
above. However, the rat did not receive any test   formulation. 
After perfusing with 10% (w/w) ethanol solution for 1 hour, 
STD1 was used as the perfusate. Perfusion by STD1 was 
allowed to equilibrate for 30 minutes, after which the perfu-
sion continued for another 30 minutes with sampling as usual. 
Following a 1 hour perfusion, STD1 was replaced with STD2. 
The same procedures were performed with STD2, and the other 
solutions STD3, STD4, STD5, and STD6 were sequentially 
perfused in the same manner. HPLC assay and data analysis 
were carried out to determine the loss of Evo and Rut from 
the STD solutions.
Statistical analysis
The results are expressed as mean ± standard deviation. 
Statistical data were analyzed by one-way analysis of 
variance, and comparisons were made with Student’s t-test 
using SPSS software (v 13.0; SPSS, Inc, Chicago, IL). 
P values less than 5% were considered to be significant. 
The cutaneous   pharmacokinetic parameters of Evo and 
Rut were calculated with WinNonLin (v 5.2; Pharsight 
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Figure 2 Pseudoternary phase diagrams of microemulsions with ethyl oleate as the oil phase. (A) represents the pseudoternary phase diagrams of microemulsions with 
Tween®-80 as surfactant (S) and ethanol as cosurfactant (Cos); (B) represents the pseudoternary phase diagrams of microemulsions with Cremophor® EL as surfactant 
and ethanol as cosurfactant (Cremophor EL/ethanol, S/Cos); (C) represents the pseudoternary phase diagrams of microemulsions with Cremophor EL as surfactant and 
polyethylene glycol 400 as cosurfactant (Cremophor EL/PEg400, S/Cos); Km represents the weight ratios of surfactant to cosurfactant.
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Corporation, Sunnyvale, CA) using noncompartmental 
analysis.
Results and discussion
Selection of components for MEs
Ethyl oleate was selected as the oil phase for satisfactory solu-
bilities of Evo and Rut. With increasing Km (the weight ratio 
of surfactant to cosurfactant), O/W ME regions increased 
in all phase diagrams. As shown in Figure 2, the barely 
  satisfactory results improved with Cremophor EL as the 
surfactant, and the largest grey area occurred with PEG400 
as the cosurfactant at the same Km value. PEG400 has a 
solubilization capacity for lipid-soluble drugs and the highest 
hydrophile–lipophile balance value among all the cosurfac-
tants, which may contribute to ME formation.
Characterization of MEs
Nine representative ME formulations were selected for 
  further screening (Table 1). According to the phase studies, 
all the selected formulations readily formed transparent MEs. 
Several surfactants and cosurfactants were used at varying 
ratios in ME preparations to fully evaluate their potential 
transdermal effects. The characteristics of the nine MEs 
(ME1 to ME9), such as mean droplet size, polydispersity, and 
viscosity, are listed in Table 2. The mean droplet sizes of the 
MEs were all below 50 nm, ranging from 10.7 nm in ME7 
to 48.1 nm in ME1. Polydispersity indices were from 0.10 
to 0.49. Increased viscosities of the systems were observed 
with increasing surfactant amounts in the ME formulations 
(Table 2). Droplets presented a spherical shape and remained 
separate when observed by transmission electron microscope 
(Figure 3). An interesting change was observed in that the 
droplet size of the drug-loaded MEs was larger than those 
without Evo and Rut. A similar phenomenon was reported 
by Chen et al17 that may be attributed to the embedding of 
Evo and Rut in the interfacial film.18,19 The pH values of all 
the MEs were in the appropriate range of 5.0–6.0.
Ex vivo skin permeation studies
The external standard method was selected for detecting 
the drugs by HPLC, and a satisfactorily high precision was 
achieved, presumably because the samples were injected into 
HPLC through a high precise autosampler and without any 
complicated prior handling (eg, centrifugation or   extraction 
with organic reagents). In general, the internal standard 
method is often adopted to increase assay precision;20 
  however, the external standard method may be preferentially 
used for greater convenience and efficiency when eligible 
precision and recovery can be realized. The mean cumula-
tive permeation rates (µg/cm2) for ME1 to ME9 vs time are 
summarized in Figure 4 and Table 2.
The permeation profiles of all the tested vehicles followed 
zero-order release kinetics. Statistical comparison of the flux in a 
24-hour period showed that all nine MEs provided higher fluxes 
than the aqueous suspension and ointment (O/W) containing the 
same dosages of ingredients. The fluxes of Evo and Rut in MEs 
were 2.55-fold to 11.36-fold and 1.17-fold to 6.33-fold higher, 
respectively, than those of aqueous   suspensions. The fluxes 
of Evo and Rut in the aqueous suspension were the lowest, 
which may be due to the fact that Evo and Rut dissolved better 
in the MEs and the ointment, leading to higher concentration 
gradients toward the skin.21 MEs provided higher fluxes than the 
ointment, perhaps because of the larger viscosity and particle 
size of the ointment compared to that of the MEs, which would 
Table 2 Microemulsion characteristics and skin permeation rates of evodiamine and rutaecarpine (mean ± standard deviation, n = 3)
Formulations Mean droplet size 
(nm)
Polydispersity  
index
Viscosity 
(mPa ⋅ s)
Skin penetration rate constants 
(μg/cm2 per h)
Evodiamine Rutaecarpine
ME1 48.1 ± 1.5 0.31 ± 0.05   48.61 ± 0.29 0.055 ± 0.001 0.016 ± 0.002
ME2 20.2 ± 1.2 0.10 ± 0.02   37.65 ± 0.14 0.125 ± 0.024 0.038 ± 0.007
ME3 47.5 ± 1.6 0.25 ± 0.06   33.08 ± 0.75 0.112 ± 0.035 0.034 ± 0.004
ME4 42.9 ± 1.6 0.32 ± 0.01   85.24 ± 0.91 0.037 ± 0.006 0.011 ± 0.003
ME5 11.3 ± 0.4 0.48 ± 0.04   53.77 ± 0.39 0.082 ± 0.012 0.015 ± 0.005
ME6 26.8 ± 1.2 0.11 ± 0.02   36.20 ± 0.27 0.060 ± 0.007 0.020 ± 0.003
ME7 29.9 ± 1.0 0.12 ± 0.01 109.18 ± 0.46 0.028 ± 0.005 0.007 ± 0.001
ME8 10.7 ± 0.6 0.49 ± 0.06   65.74 ± 0.82 0.051 ± 0.004 0.013 ± 0.005
ME9 39.6 ± 0.7 0.37 ± 0.07   41.02 ± 0.33 0.058 ± 0.006 0.017 ± 0.004
Suspension – – – 0.011 ± 0.002 0.006 ± 0.001
Ointment – – – 0.027 ± 0.003 0.009 ± 0.001
Abbreviation: mPa ⋅ s, millipascal seconds.
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have delayed the diffusion of Evo and Rut from the ointment 
toward the skin surface. Another factor in the ME-mediated 
faster permeation may be related to the reduction in interfacial 
tension between the skin and vehicle, resulting from its close 
contact with skin lipids, as reported in the literature.22 Among 
the nine MEs, ME2 provided the highest fluxes of Evo and Rut 
(0.125 ± 0.024 µg/cm2/hour and 0.038 ± 0.007 µg/cm2/hour, 
respectively), while the fluxes of ME7, with the   highest 
viscosity, were the   lowest (0.028 ± 0.005 µg/cm2/hour and 
0.007 ± 0.001 µg/cm2/hour, respectively) (Table 2).   Permeation 
of each compound was reduced with a higher proportion 
of surfactant, while the corresponding viscosity increased. 
Viscosity has been reported to play an important role in the 
release of drugs into the receptor compartment, because drug 
diffusion through the double layer of the ME may comprise a 
rate-determining step.23 The ME2 droplet size was the small-
est, along with ME5 and ME8, which had higher polydiversity 
and viscosity values than ME2. This may have led to the 
ingredients in ME2 easily permeating through the stratum 
corneum of the skin. Notably, as can be seen in Table 2 and 
Figure 4, the permeation amounts and flux rates of Evo and 
Rut both declined with an increase in the amount of surfactants. 
Similar results were reported previously.24 An explanation for 
this is that the thermodynamic activities of the drugs in the ME 
decreases with higher concentration of surfactants.25
ME2 was selected for further studies because it exhibited 
the highest permeation and solubility for Evo and Rut. To 
further optimize the formulation, the effects of drug loading, 
water weight fraction, and penetration enhancers on the skin 
permeation of Evo and Rut were investigated using ME2.
The effects of drug loading in the ME on the penetration 
rates of Evo and Rut are shown in Figure 5. The skin per-
meation of each drug was proportional to drug loading until 
the solubility limit was reached. There was no significant 
increase in drug permeation when drug loading was increased 
from 1% to 2% (P . 0.05).
The influence of water weight fraction of the ME on skin 
permeation of each drug is illustrated in Figure 6. The high-
est permeation rates for both drugs were obtained when the 
water content was 50% (w/w). A decreasing trend in the skin 
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Figure 5 Ex vivo rat skin permeation profiles of evodiamine (a) and rutaecarpine (b) 
from microemulsions with different drug loadings (n = 3).
Figure 3 Transmission electron microscopy of evodiamine and rutaecarpine-loaded 
microemulsion ME2.
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fluxes of Evo and Rut was observed when the water weight 
fraction in the ME was greater or less than 50%. These results 
suggest that drug skin flux may be improved by choosing the 
appropriate water content for MEs. With an increased water 
content, ME viscosity would decrease, which may facilitate 
the gathering of droplets on the skin surface to form a high 
concentration gradient, thus enhancing the permeation of Evo 
and Rut.21 On the other hand, excess water content may lead 
to droplet concentration being too low to form an effective 
concentration gradient of the drugs toward the skin, thus 
reducing the flux of Evo and Rut.26
To maximize the permeation rate of the ME, transdermal 
enhancers were investigated. Azone and several volatile oils 
were added to the MEs at different proportions to evaluate 
their influence on permeation performance. All the MEs 
with volatile oils presented higher permeation rates for Evo 
and Rut. As shown in Figure 7, the flux generally increased 
with rising proportions of volatile oils. However, when the 
volatile oil reached a certain point, the permeation rates 
showed a downward trend. A large amount of volatile oils 
may form a gel on the surface of the MEs and increase the 
viscosity, thus reducing the diffusion velocity and decreasing 
permeation rates. Among the tested volatile oils, pennyroyal 
showed perfect permeation enhancement. When 5% pen-
nyroyal was incorporated into ME, the permeation rates of 
Evo and Rut increased from 0.125 ± 0.031 µg/cm2/hour and 
0.038 ± 0.011 µg/cm2/hour to 0.572 ± 0.096 µg/cm2/hour 
and 0.274 ± 0.014 µg/cm2/hour, respectively. However, 
the volatility of pennyroyal may lead to unstable fluxes of 
the ingredients permeating through the skin, especially for 
external applications. The permeation enhancement effect 
of azone on Evo and Rut is illustrated in Figure 8. With the 
addition of azone to the ME, the permeation rates of both 
drugs increased; the highest skin permeation for each drug 
was observed when azone was added at 1.0% (w/w). No 
significant difference between azone and pennyroyal was 
detected at the optimum level. Azone has been extensively 
used as a permeation enhancer because of its stable physi-
cal and chemical properties and its safety for human use.27 
Therefore, azone was suitable as a permeation enhancer for 
Evo and Rut-loaded MEs.
Stability studies
Centrifugation tests (13,000 rpm for 30 minutes) demon-
strated no delamination of the ME formulations, indicating 
that the MEs had good physical stability. The Evo and 
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from microemulsions in the presence of various volatile oils (n = 3).
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Rut-loaded MEs, prepared according to the optimal formu-
lation, were physicochemically stable after storage at 25°C 
for 6 months. Droplet sizes were measured monthly and 
changes within a range of 20.8 ± 0.9 nm to 22.4 ± 1.8 nm 
were observed during the test period. However, the data 
presented no significant differences (P . 0.05).
Ex vivo and in vivo recovery validation  
of microdialysis
Five types of perfusates were evaluated using ex vivo recovery 
experiments: phosphate buffer saline (pH 6.4), phosphate 
buffer saline (pH 7.4), normal saline, 10%   ethanol–water 
solution, and 20% ethanol–water solution. The 10% and 
20% ethanol–water solutions showed the best recoveries, 
while the presence of Evo and Rut was hard to detect in the 
  others, perhaps due to the greater solubilities of Evo and Rut 
in 10% and 20% ethanol–water solutions. Besides having 
good solubility for the drug and providing good sink condi-
tions, a suitable perfusate must cause little or no harm. In 
this respect, high ethanol content may change the properties 
of the extracellular fluids around the probe and further influ-
ence drug distribution. Therefore, the 10% ethanol–water 
solution was confirmed as the perfusate for ex vivo and 
in vivo   studies. No obvious skin injury was observed during 
the in vivo experiments.
From the ex vivo recovery validation studies using 
STD1 to STD6 as perfusates, a linear correlation was found 
between the drug concentrations in the perfusate and the 
dialysate (Evo: Cd = 0.61, Cp = −0.06, r2 = 0.995; Rut: 
Cd = 0.67, Cp = -0.09, r2 = 0.989). This correlation implied 
that ex vivo recovery by retrodialysis was independent 
of perfusate concentrations, validating the feasibility of 
the microdialysis technique for detecting true unbound 
extracellular levels of Evo and Rut. The ex vivo recovery 
of both Evo and Rut were the highest at a flow rate of 
3.33 µL/minute. In general, the higher the perfusion flow 
rate, the lower the RR.11 Our discovery of a decline in 
RR with an increase in flow rates (from 3.33 L/minute to 
8.33 µL/minute) is consistent with this. A lower perfusate 
flow allowed more time for the drugs to diffuse through 
the dialysis membrane, thus enhancing the equilibrium 
process. Nevertheless, a slight decrease in ex vivo recovery 
was observed at the lowest flow rate of 1.67 µL/minute 
compared to 3.33 µL/minute. A potential reason may be 
the adhesion of drug molecules to the dialysis membrane, 
resulting from an extended equilibration time. Therefore, 
a flow rate of 3.33 µL/minute, with the highest ex vivo 
recovery, was determined as the optimum.
The general recovery of microdialysis probes (positive 
dialysis) was 45.42% ± 0.96% for Evo and 43.75% ± 0.63% 
for Rut using STD3 as the medium. Since the in vivo recovery 
of positive dialysis cannot be directly determined, a general 
practice is to investigate using the retrodialysis method, but 
one must ensure consistent results from the two dialysis 
methods. In the ex vivo studies, no significant difference 
was observed between the recoveries from dialysis and 
  retrodialysis (P . 0.05) with 10% ethanol solution as per-
fusate at a flow of 3.33 µL/minute.
In vivo recovery was lower than ex vivo recovery, as 
expected. Greater diffusional resistance in the living tissue 
led to a lower in vivo recovery, and volume distribution and 
clearance of the drugs may also contribute to the low in 
vivo recovery. As with ex vivo recovery by retrodialysis, a 
linear correlation was found between the drug   concentrations 
in the perfusate and the dialysate for in vivo recovery by 
retrodialysis (Evo: Cd = 0.76, Cp = −0.09, r2 = 0.990; Rut: 
Cd = 0.81, Cp = −0.09, r2 = 0.994). This correlation confirmed 
that in vivo recovery by retrodialysis was independent of 
perfusate concentrations, and can be used to correct the data 
from in vivo microdialysis samplings (the maximum recovery 
values of 33.71% ± 0.23% for Evo and 30.19% ± 0.31% for 
Rut were used).
The recovery validation studies confirmed that both 
ex vivo and in vivo recoveries were independent of analyte 
concentrations. In vivo recovery was lower than ex vivo 
recovery; this may be due to different diffusion environ-
ments in the living tissue compared to simple solutions. 
Therefore, the living tissue, rather than the microdialysis 
probe, was found to be the rate-limiting factor for diffu-
sion in the dialysis. Since no time-dependent changes in 
recovery were observed, the retrodialysis-by-drug method 
was reliable for correction.
In vivo microdialysis
Time-concentration profiles of Evo and Rut after topical 
application of the formulations as ME, ointment, and tincture 
on abdominal skin in rats are depicted in Figure 9. Relatively 
smooth curves were observed for ME and tincture applica-
tions, indicating steady and even drug absorption through the 
abdominal skin (Figure 9A). In contrast, the curve for oint-
ment application was irregular with constant rise and falls, 
which implied unstable transdermal drug absorption (Fig-
ure 9A). Unlike the ME and tincture formulations which were 
fluids, the ointment formulation was semisolid.   Therefore, 
the distribution of drug molecules within the ointment 
and their penetration through the skin were not as even for 
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ME and tincture, potentially contributing to fluctuations in 
the transdermal behavior of Evo molecules. A few   sudden 
increases in Evo concentrations were possibly caused by 
some ointment passing through the inlet puncture of the 
probe to be directly captured in the dialysate. Similar pat-
terns were observed for Rut (Figure 9B), but the fluctuations 
were milder.
The maximum concentration (Cmax) of the drugs 
from ME were the highest (Evo: 18.23 ± 1.54 ng/mL; 
Rut: 16.04 ± 0.96 ng/mL), and the area under the curve 
(AUC0–t) of Evo and Rut was 1.52-fold and 2.27-fold higher 
than those of ointment, and 3.06-fold and 4.23-fold higher 
than those of tincture, respectively (Table 3). Evidently, 
the transdermal concentrations and cumulative amounts of 
Evo and Rut were the highest for ME, while the aqueous 
tincture presented the lowest concentrations and amounts. 
Additionally, the cutaneous penetration rates of drugs in 
ointment and tincture applications were relatively slow 
(the curves climbed gradually) compared to the ME appli-
cation, where the drug concentrations rose steeply within 
30 minutes (Figure 9).
Topically applied MEs have been shown to significantly 
increase the cutaneous absorption of drugs.10 The increased 
absorption of drugs is attributed to skin penetration enhance-
ment by the carrier, which has thermodynamic stability, low 
viscosity, high surface area (high solubilization capacity), 
and very small droplet size. The potential strategies to 
enhance drug penetration through the skin include altering 
the skin physiology and modifying the formulation to influ-
ence drug partition, diffusion, or solubility. The oil-soluble 
Evo and Rut were solubilized in ME droplets, which passed 
through the stratum corneum with ease to release the drugs 
in intercellular spaces. Furthermore, ethyl oleate as the oil 
phase acted as a penetration enhancer that increased skin 
permeability.28 In the cases of ointment and tincture, the 
solubilities of Evo and Rut were rather low, and the fluidity 
of ointment was poor, while tincture had the problem of 
ethanol volatilization. Thus, transdermal concentrations of 
Evo and Rut molecules through the abdominal skin in rats 
were higher for the ME formulation than the conventional 
form of ointment or tincture.
Time-concentration profiles of Evo and Rut after   topical 
application of the ME on abdomen, chest, and shoulder 
of rats are depicted in Figure 10. Evo concentrations in 
the abdomen, shoulder, and chest regions increased dur-
ing the initial 100 minutes before reaching a plateau, 
and the concentrations stayed relatively stable afterward 
(Figure 10A). However, Cmax was different in the three 
regions: 18.23 ± 1.54 ng/mL for abdominal application, 
8.20 ± 0.91 ng/mL for chest, and 4.24 ± 0.49 ng/mL for 
shoulder (Table 4). The same patterns were observed for 
Rut concentrations (Figure 10B and Table 4), which were 
only slightly lower than those of Evo.
Evo and Rut transdermal concentrations climbed sharply 
during the initial 30 minutes and were significantly absorbed 
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Figure 9 Time course of evodiamine (A) and rutaecarpine (B) concentrations 
sampled after the administration of drug-containing microemulsion, ointment, and 
tincture on the abdominal skin of Sprague-Dawley rats over 10 hours (n = 5).
Table 3 Cutaneous pharmacokinetic parameters of evodiamine and rutaecarpine from various formulations in rats (mean ± standard 
deviation, n = 5)
Parameter Evodiamine Rutaecarpine
Microemulsion Ointment Tincture Microemulsion Ointment Tincture
Tmax (minutes)   480.00 ± 21.35   360.00 ± 25.09   390.00 ± 19.38   450.00 ± 17.28   360.00 ± 11.65   420.00 ± 16.50
Cmax (ng/mL)   18.23 ± 1.54   16.40 ± 1.43     7.62 ± 0.73   16.04 ± 0.96     8.53 ± 0.48     5.92 ± 0.33
MRT0–t (minutes)   307.77 ± 10.28   329.15 ± 18.37   349.18 ± 9.24   319.11 ± 25.11   318.91 ± 12.46   322.67 ± 5.42
AUC0–t (ng/mL × minutes) 9368.34 ± 104.52 6163.65 ± 82.51 3065.16 ± 65.04 7878.33 ± 87.23 3473.64 ± 63.08 1861.56 ± 27.96
Abbreviations: AUC, area under the curve; Cmax, maximum concentration; MRT, mean residence time; Tmax, time to reach Cmax.
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by abdominal skin, with the concentrations being more than 
double those of chest skin, and four times higher than those 
of shoulder skin. The reason may be that the stratum corneum 
is the thinnest in abdominal skin, followed by chest skin, and 
is relatively thick in shoulder skin.29 As the stratum corneum 
serves as the main barrier for transdermal drug delivery, drug 
molecules most easily penetrate through the abdominal skin, 
resulting in the highest transdermal concentrations of Evo 
and Rut. This finding is in accordance with the results of ex 
vivo transdermal diffusion studies using excised rat skin from 
corresponding sites.
Time-concentration profiles of Evo and Rut after topical 
application of the ME on the abdominal skin of rats for a 
defined period of time (3 hours) exhibited analogous patterns 
(Figure 11). The concentrations of Evo and Rut climbed 
sharply during the initial 30 minutes, reached maximum 
values around 120 minutes, and maintained a plateau until 
180 minutes, after which the ME was withdrawn. Then, Evo 
and Rut concentrations declined as no formulation was applied. 
However, the decline in concentrations was gradual and not 
steep. A slow reduction was observed after 200 minutes, and 
a relatively big fall to nearly half of Cmax occurred between 
240–340 minutes, followed by a mild decrease again.
The variation in transdermal concentration trends of Evo 
and Rut indicated that there was some storage of drug mol-
ecules in the skin after the ME was withdrawn. The stocked 
drug molecules were released to maintain their transdermal 
concentrations in the absence of a formulation supply. This 
drug reservoir was able to last for a period of time, with the 
drug concentrations decreasing gradually before depletion. 
The stratum corneum is a strong candidate for the reservoir, 
particularly its intercellular lipid bilayers, because Evo and 
Rut can accumulate in lipophilic compartments. Furthermore, 
the unique structure of ME droplets may also potentially 
contribute to this retention phenomenon.
The ME formulation enhanced skin penetration and 
absorption of Evo and Rut molecules, relative to ointment 
and tincture. Furthermore, the cutaneous penetration rates 
of Evo and Rut were expectedly much higher for ME. The 
ME was more efficiently used when applied on abdominal 
skin in rats, resulting in greater permeation and absorption 
of Evo and Rut. Hence, the abdomen with a relatively thin 
skin layer (thin stratum corneum) was demonstrated to be 
an ideal location for transdermal drug delivery, far better 
than chest or shoulder. It was further discovered that ME 
application resulted in the formation of a drug reservoir in 
the skin, which released Evo and Rut for an extended period 
after the drug formulation was withdrawn. This resulted in 
a prolonged effect of the ME formulation.
In vivo experiments were carried out to investigate the 
relevance of ME as a transdermal route for administration of 
Evo and Rut. Being a superior technique to directly assess 
unbound extracellular drug levels in the skin, in vivo microdi-
alysis proved to be a sensitive and less invasive technique for 
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Figure 10 Time course of evodiamine (A) and rutaecarpine (B) concentrations 
sampled after microemulsion administration on the abdomen, shoulder, and chest 
regions of Sprague-Dawley rats over 10 hours (n = 5).
Table 4 Cutaneous pharmacokinetic parameters of evodiamine and rutaecarpine from various skin regions in rats (mean ± standard 
deviation, n = 5)
Parameter Evodiamine Rutaecarpine
Abdomen Chest Shoulder Abdomen Chest Shoulder
Tmax (minutes)   480.00 ± 21.35   120.00 ± 11.32   180.00 ± 12.58   450.00 ± 17.28   150.00 ± 6.94   180.00 ± 13.66
Cmax (ng/mL)   18.23 ± 1.54     8.20 ± 0.91     4.24 ± 0.49   16.04 ± 0.96     7.11 ± 0.75     3.77 ± 0.52
MRT0–t (minutes)   307.77 ± 10.28   308.69 ± 25.87   312.60 ± 14.30   319.11 ± 25.11   303.14 ± 8.72   290.37 ± 21.43
AUC0–t (ng/mL × minutes) 9368.34 ± 104.52 3808.92 ± 86.13 2088.33 ± 91.36 7878.33 ± 87.23 3358.77 ± 69.54 1653.84 ± 71.20
Abbreviations: AUC, area under the curve; Cmax, maximum concentration; MRT, mean residence time; Tmax, time to reach Cmax.
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monitoring the real-time true transdermal concentrations of 
analytes and their cutaneous penetration rates. The HPLC 
turned out to be rather compatible with direct injection of 
aqueous microdialysis samples. The importance of perform-
ing recovery validation studies for data interpretation and 
accuracy of determinations was demonstrated.
Conclusion
An O/W ME containing Evo and Rut was formulated for 
transdermal delivery. Ex vivo skin permeation and in vivo 
microdialysis were used to evaluate the percutaneous pene-
tration of drugs. The data indicate that the transdermal route 
is an effective way to deliver the two active alkaloids.
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Figure 11 Time course of evodiamine (Evo) and rutaecarpine (Rut) concentrations 
sampled after drug microemulsion administration (removed after 3 hours) on the 
abdominal skin of Sprague-Dawley rats over 10 hours (n = 5).
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